DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Ganitumab
Ganitumab
IGF System in Sarcomas: a Crucial Pathway with Many Unknowns to Exploit for Therapy
Therapeutic Targeting of the IGF Axis
Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy
2017 Immuno-Oncology Medicines in Development
The Two Tontti Tudiul Lui Hi Ha Unit
(12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub
Agents Available Under CTEP Collaborative Agreements for Clinical and Non-Clinical Studies 1 As of 7/28/2021
Development and Preclinical Evaluation of Cixutumumab Drug
The IGF-II–Insulin Receptor Isoform-A Autocrine Signal in Cancer: Actionable Perspectives
(INN) for Biological and Biotechnological Substances
Ep 3321281 A1
Safety and Pharmacokinetics of Ganitumab (AMG 479) Combined with Sorafenib, Panitumumab, Erlotinib, Or Gemcitabine in Patients with Advanced Solid Tumors
Breast Cancer 1
Anticancer Activity of the Type I Insulin-Like Growth Factor Receptor Antagonist, Ganitumab, in Combination with the Death Receptor 5 Agonist, Conatumumab
Ganitumab (AMG 479) Inhibits IGF-II–Dependent Ovarian Cancer Growth and Potentiates Platinum-Based Chemotherapy
Breast Cancer - Invasive Jane Doe 1/15/2020
INN Working Document 05.179 Update 2011
Stembook 2018.Pdf
Top View
A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
IUPAC Glossary of Terms Used in Immunotoxicology (IUPAC Recommendations 2012)*
WO 2013/169611 Al 14 November 2013 (14.11.2013) P O P C T
12Th European Breast Cancer Conference (EBCC-12) 32Nd EORTC-NCI-AACR Sympos
(INN) for Biological and Biotechnological Substances
Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies
Clinical Applications and Future Direction of Insulin-Like Growth Factor-1 Receptor Pathway Blockade Wade T
( 12 ) United States Patent
Role of Immunotherapy in Ewing Sarcoma
F1H Soft Tissue Sarcoma (NOS) Sample Report.Pdf
Clinical Applications and Future Direction of Insulin-Like Growth Factor-1 Receptor Pathway Blockade Wade T
Open Full Page
Snapshot: Breast Cancer Kornelia Polyak and Otto Metzger Filho Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215 USA
(AMG 479) Combined with Sorafenib, Panitumumab, Erlotinib, Or Gemcitabine in Patients with Advanced Solid Tumors
Anti-IGF-1R Monoclonal Antibody
An Overview of the Current Status of Engineered Therapeutic Monoclonal Antibodies
Anti-Insulin-Like Growth Factor Therapy in Breast Cancer
Unraveling the Resistance of IGF-Pathway Inhibition in Ewing Sarcoma
Combination Therapy Approaches to Target Insulin-Like Growth Factor Receptor Signaling in Breast Cancer
Randomized Phase Ib/II Trial of Rilotumumab Or Ganitumab with Panitumumab
Oncofocus Patient Test Report
Supplementary Tables and Figures Section 1. Distribution of CDR-H3
Global Oncology Trend Report a Review of 2015 and Outlook to 2020
Effects on Cancer Therapy
Adjuvant Chemotherapy
PCORI Topic Brief: Comparative Effectiveness of Second-Line
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Disrupting Insulin and IGF Receptor Function in Cancer
The Impact of Timing of EGFR and IGF-1R Inhibition for Sensitizing Head and Neck Cancer to Radiation
Lessons to Learn for Adequate Targeted Therapy Development in Metastatic Colorectal Cancer Patients
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Cancer PRESENTEDBYAMERICA ’ SBIOPHARMACEUTICALRESEARCHCOMPANIES Nearly 900 Medicines and Vaccines in Testing Offer Hope in the Fight Against Cancer
Long-Term Outcomes of Neoadjuvant Treatment of HER2-Positive Breast Cancer
(INN) for Biological and Biotechnological Substances
Targeting Obesity-Related Dysfunction in Hormonally Driven Cancers
UCSF UC San Francisco Electronic Theses and Dissertations
Ep 3088005 A1
The Role of the Insulin-Like Growth Factor Axis in Osseous Metastasis
Recent Advances in Monoclonal Antibody Therapy for Colorectal Cancers
Mapt Breast Sample Report EXS50068 0221
SP-2577 (Seclidemstat) for the Treatment of Relapsed Or Refractory Ewing Sarcoma
Influence of Antigen Mass on the Pharmacokinetics of Therapeutic
Ganitumab/Rilotumumab
111In and 225Ac-Labeled Cixutumumab for Imaging and Alpha
IGF-1R: SUMO-Ing Its Weight in Chemoresistant Colorectal Cancer
Comprehensive Review of Targeted Therapy for Colorectal Cancer
IGF1R Blockade with Ganitumab Results in Systemic Effects on the GH–IGF Axis in Mice
Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities
Downloaded from Bioscientifica.Com at 10/01/2021 06:50:56AM Via Free Access Research a Dasari Et Al